On August 20, 2026, the trial registry listed an update for a study related to the angiotensin II pathway involving valsartan. The trial, titled "Effects of VALsartan On atRIAl Mitral Regurgitation (VALORIA) - Pilot," is registered under identifier NCT07539298. Its current status is recruiting. The trial is designated as Phase 2/3. No results have been posted for this study as of the update date. The trial is examining valsartan, an angiotensin receptor blocker, in relation to atrial mitral regurgitation, according to the registered title. No additional details on trial design, endpoints, or outcomes were provided in this update. Readers should note that recruiting status indicates the trial is currently enrolling participants and has not concluded. For further context on angiotensin II as a compound and its regulatory status, readers are encouraged to consult the compound overview.
Angiotensin II-Related Trial VALORIA Update: Now Recruiting, Phase 2/3
See the full angiotensin ii overview
Source: https://clinicaltrials.gov/study/NCT07539298